CN104592361B - 砗磲肽在制备抗血栓、安神镇定药物和保健品的应用及其制备方法 - Google Patents
砗磲肽在制备抗血栓、安神镇定药物和保健品的应用及其制备方法 Download PDFInfo
- Publication number
- CN104592361B CN104592361B CN201510060448.7A CN201510060448A CN104592361B CN 104592361 B CN104592361 B CN 104592361B CN 201510060448 A CN201510060448 A CN 201510060448A CN 104592361 B CN104592361 B CN 104592361B
- Authority
- CN
- China
- Prior art keywords
- giant clam
- calm
- peptide
- drug
- health products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 49
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 18
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 230000036541 health Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 210000005036 nerve Anatomy 0.000 title description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 230000002936 tranquilizing effect Effects 0.000 claims abstract description 4
- 230000032361 posttranscriptional gene silencing Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 15
- 208000007536 Thrombosis Diseases 0.000 abstract description 11
- 230000000740 bleeding effect Effects 0.000 abstract description 10
- 206010053567 Coagulopathies Diseases 0.000 abstract description 9
- 230000035602 clotting Effects 0.000 abstract description 9
- 235000020639 clam Nutrition 0.000 description 37
- 239000000047 product Substances 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 206010010904 Convulsion Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000036461 convulsion Effects 0.000 description 10
- 230000001914 calming effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940127218 antiplatelet drug Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 235000015096 spirit Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010070741 Tachypleus tridentatus tachyplesin peptide Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- -1 adenosine diphosphates Chemical class 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940019334 heparin group antithrombotic drug Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229940023492 oral liquid product Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- ZJQFYZCNRTZAIM-PMXBASNASA-N tachyplesin Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@H](C(N[C@H]2CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](N)CCCCN)CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZJQFYZCNRTZAIM-PMXBASNASA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
多肽名称(10μg/ml) | 血小板最大聚集率(Ω) | 抑制率/% |
MD-03 | 9.60 | 45.8 |
MD-09 | 7.54 | 50.1 |
MD-19 | 6.87 | 55.2 |
MD-25 | 8.21 | 47.1 |
MD-33 | 7.56 | 53.1 |
MD-42 | 7.69 | 53.2 |
MD-57 | 7.42 | 54.0 |
MD-59 | 7.27 | 54.5 |
MD-77 | 7.56 | 53.7 |
MD-82 | 7.99 | 53.5 |
MD-86 | 6.98 | 55.0 |
MD-93 | 7.54 | 53.9 |
超纯水对照 | 17.82 | 0 |
多肽名称(10μg/ml) | 血小板最大聚集率(Ω) | 抑制率/% |
MD-03 | 5.0 | 53.0 |
MD-09 | 4.1 | 59.1 |
MD-19 | 4.2 | 58.7 |
MD-25 | 4.3 | 58.1 |
MD-33 | 4.2 | 58.7 |
MD-42 | 4.1 | 59.1 |
MD-57 | 4.2 | 58.7 |
MD-59 | 4.3 | 58.1 |
MD-77 | 4.4 | 57.2 |
MD-82 | 4.5 | 56.1 |
MD-86 | 4.1 | 59.1 |
MD-93 | 4.2 | 58.7 |
超纯水对照 | 10.2 | 0 |
多肽名称(100μg/kg) | 5分钟平均堵塞率/% |
MD-03 | 36 |
MD-09 | 17 |
MD-19 | 16 |
MD-25 | 15 |
MD-33 | 15 |
MD-42 | 16 |
MD-57 | 14 |
MD-59 | 16 |
MD-77 | 15 |
MD-82 | 17 |
MD-86 | 14 |
MD-93 | 16 |
超纯水对照 | 80.0 |
血栓通组30mg/kg | 8.2 |
肝素组1600U/kg | 10.2 |
多肽名称(100μg/kg) | BT(min) | CT(min) |
MD-03 | 21.3 | 1.3 |
MD-09 | 24.1 | 4.2 |
MD-19 | 25.2 | 4.1 |
MD-25 | 25.6 | 4.2 |
MD-33 | 25.7 | 4.5 |
MD-42 | 26.1 | 4.3 |
MD-57 | 26.3 | 4.0 |
MD-59 | 25.9 | 4.1 |
MD-77 | 25.6 | 4.2 |
MD-82 | 25.7 | 4.1 |
MD-86 | 25.9 | 3.8 |
MD-93 | 25.6 | 3.9 |
对照组 | 11.2 | 1.3 |
血栓通组 | 19.2 | 3.0 |
多肽名称(100μg/kg) | 活动频率 |
MD-03 | +++ |
MD-09 | + |
MD-19 | + |
MD-25 | + |
MD-33 | + |
MD-42 | + |
MD-57 | + |
MD-59 | ++ |
MD-77 | + |
MD-82 | + |
MD-86 | + |
MD-93 | ++ |
对照组 | +++++ |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510060448.7A CN104592361B (zh) | 2015-02-05 | 2015-02-05 | 砗磲肽在制备抗血栓、安神镇定药物和保健品的应用及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510060448.7A CN104592361B (zh) | 2015-02-05 | 2015-02-05 | 砗磲肽在制备抗血栓、安神镇定药物和保健品的应用及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104592361A CN104592361A (zh) | 2015-05-06 |
CN104592361B true CN104592361B (zh) | 2018-07-13 |
Family
ID=53118452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510060448.7A Active CN104592361B (zh) | 2015-02-05 | 2015-02-05 | 砗磲肽在制备抗血栓、安神镇定药物和保健品的应用及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104592361B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188691A (zh) * | 2011-04-19 | 2011-09-21 | 广东医学院 | 鲎素肽在制备抗血栓药物和保健品的应用及其制备方法 |
CN103275191A (zh) * | 2013-06-19 | 2013-09-04 | 天津兰瑞生物技术有限公司 | 一种大量快速提取鲎素肽的方法 |
-
2015
- 2015-02-05 CN CN201510060448.7A patent/CN104592361B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188691A (zh) * | 2011-04-19 | 2011-09-21 | 广东医学院 | 鲎素肽在制备抗血栓药物和保健品的应用及其制备方法 |
CN103275191A (zh) * | 2013-06-19 | 2013-09-04 | 天津兰瑞生物技术有限公司 | 一种大量快速提取鲎素肽的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104592361A (zh) | 2015-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oduola et al. | Antisickling agent in an extract of unripe pawpaw (Carica papaya): is it real? | |
CN104774243A (zh) | 一种麒麟菜多肽提取物及其制备方法和应用 | |
CN102188691B (zh) | 鲎素肽在制备抗血栓药物和保健品的应用及其制备方法 | |
CN101322810B (zh) | 一种治疗上呼吸道感染的药物组合物 | |
CN104592361B (zh) | 砗磲肽在制备抗血栓、安神镇定药物和保健品的应用及其制备方法 | |
CN103463622B (zh) | 姚虻抗血栓多肽vasotab TY的应用 | |
CN103933142B (zh) | 一种治疗疼痛的药膏及其制备方法、使用方法 | |
CN113876818A (zh) | 预防脑卒中的复方灵芝孢子油提取物及其制备方法和应用 | |
CN101647567B (zh) | 一种灵芝液体制剂及其制备方法 | |
CN110201024A (zh) | 一种促进创面愈合的含干细胞提取物的组合物及其用途 | |
CN102451249B (zh) | 一种治疗烧伤、烫伤的药物及其应用 | |
CN110393796A (zh) | 一种治疗骨关节疼痛的外用膏药及其制备方法 | |
CN102274460A (zh) | 一种治疗急慢性扭挫伤、风湿、类风湿疾病的藏药气雾剂 | |
CN107468722A (zh) | 一种生物质微纤维软膏及其制备方法 | |
CN106943548A (zh) | 高粱根提取物、其制备方法及用途 | |
CN102940676B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN107638436A (zh) | 一种药物组合物在制备治疗皮下出血的药物中的应用 | |
CN100998651B (zh) | 治疗血栓栓塞性疾病的药物及其制备方法 | |
CN107006653A (zh) | 一种西蓝花幼苗三泡台茶的生产方法 | |
CN106138913A (zh) | 一种治疗脑血栓的药物组合物及其制备方法 | |
CN104940237B (zh) | 一种鳄鱼血去蛋白提取物及其提取方法和应用 | |
CN104546953A (zh) | 一种江南卷柏提取物在制备治疗血栓性疾病药物中的应用 | |
CN104906416B (zh) | 一种用于治疗阴虚火旺型紫癜的中药组合物 | |
CN104906210A (zh) | 治疗霉菌性阴道炎中药外用洗液及其制备方法 | |
CN101721510B (zh) | 治疗头痛或偏头痛的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 710064 Xi'an, South Shaanxi,, Chang'an University Applicant after: Ma Shujuan Address before: 721300, Shaanxi province Baoji Chencang phosphate fertilizer plant family hospital building No. 5 building two units on the first floor of the West Applicant before: Ma Shujuan |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180608 Address after: 264207 Shandong Weihai Nanhai New District Binhai Road North, Longhai Road East Applicant after: REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. Address before: 710064 Chang'an University, south two ring road, Xi'an, Shaanxi Applicant before: Ma Shujuan |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Tridacna peptide in preparation of antithrombotic, sedative and health care products and its preparation method Effective date of registration: 20210408 Granted publication date: 20180713 Pledgee: Bank of China Limited Weihai Wendeng sub branch Pledgor: REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. Registration number: Y2021980002490 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220609 Granted publication date: 20180713 Pledgee: Bank of China Limited Weihai Wendeng sub branch Pledgor: REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. Registration number: Y2021980002490 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of tridentate peptide in preparation of antithrombotic, sedative and health products and its preparation method Effective date of registration: 20220610 Granted publication date: 20180713 Pledgee: Bank of China Limited Weihai Wendeng sub branch Pledgor: REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. Registration number: Y2022980007380 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230630 Granted publication date: 20180713 Pledgee: Bank of China Limited Weihai Wendeng sub branch Pledgor: REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. Registration number: Y2022980007380 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application and preparation method of Tridacna peptide in the preparation of antithrombotic, sedative, and health products Effective date of registration: 20230703 Granted publication date: 20180713 Pledgee: Bank of China Limited Weihai Wendeng sub branch Pledgor: REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. Registration number: Y2023980047222 |